Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls

European Neuropsychopharmacology

Volumn 25, Issue 1, 2015, Pages 133-140

  Pålsson, Erik ^a   Jakobsson, Joel ^a   Södersten, Kristoffer ^a   Fujita, Yuko ^b   Sellgren, Carl ^c   Ekman, Carl Johan ^c   Ågren, Hans ^a   Hashimoto, Kenji ^b   Landén, Mikael ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHIBA UNIVERSITY   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bipolar disorder; Cerebrospinal fluid; Glutamic acid; N methyl d aspartate; Serum

Indexed keywords

ANTIDEPRESSANT AGENT; DEXTRO SERINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; SERINE; VALPROIC ACID;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BIPOLAR DISORDER; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; SERUM; SIGNAL TRANSDUCTION; BLOOD; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

ADULT; BIPOLAR DISORDER; FEMALE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SERINE;

EID: 84920486612     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.11.001     Document Type: Article

References (45)

1. Akiyama T., Kobayashi K., Higashikage A., Sato J., Yoshinaga H. CSF/plasma ratios of amino acids: reference data and transports in children. Brain Dev. 2012, 36(1):3-9.
2. Altamura C.A., Mauri M.C., Ferrara A., Moro A.R., D'Andrea G., Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 1993, 150:1731-1733.
3. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B: Stat. Methodol. 1995, 57:289-300.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
5. Brouwer A., Luykx J.J., van Boxmeer L., Bakker S.C., Kahn R.S. NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: a meta-analysis of case-control studies. Neurosci. Biobehav. Rev. 2013, 37:1587-1596.
6. Castro-Gago M., Rodrigo-Saez E., Novo-Rodriguez I., Camina M.F., Rodriguez-Segade S. Hyperaminoacidemia in epileptic children treated with valproic acid. Child's Nerv. Syst. 1990, 6:434-436.
7. Dixon J.F., Los G.V., Hokin L.E. Lithium stimulates glutamate "release" and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-d-aspartate receptor in monkey and mouse cerebral cortex slices. Proc. Natl. Acad. Sci. USA 1994, 91:8358-8362.
8. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
9. Ekman C.J., Lind J., Ryden E., Ingvar M., Landen M. Manic episodes are associated with grey matter volume reduction-a voxel-based morphometry brain analysis. Acta Psychiatr. Scand. 2010, 122:507-515.
10. Frye M.A., Tsai G.E., Huggins T., Coyle J.T., Post R.M. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol. Psychiatry 2007, 61:162-166.
11. Fukushima T., Kawai J., Imai K., Toyo'oka T. Simultaneous determination of d- and l-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed. Chromatogr. 2004, 18:813-819.
12. Gigante A.D., Bond D.J., Lafer B., Lam R.W., Young L.T., Yatham L.N. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012, 14:478-487.
13. Guy W. ECDEU Assessment Manual For Psychopharmacology. Department of Health, Education and Welfare, Rockville, United States 1976, 218-222.
14. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 2005, 5:6.
15. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29:767-769.
16. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
17. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007, 62:1310-1316.
18. Hawkins R.A., O'Kane R.L., Simpson I.A., Vina J.R. Structure of the blood-brain barrier and its role in the transport of amino acids. J. Nutr. 2006, 136:218S-226S.
19. Heresco-Levy U., Bar G., Levin R., Ermilov M., Ebstein R.P., Javitt D.C. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr. Res. 2007, 91:14-21.
20. Hons J., Zirko R., Ulrychova M., Cermakova E., Doubek P., Libiger J. Glycine serum level in schizophrenia: relation to negative symptoms. Psychiatry Res. 2010, 176:103-108.
21. Jakobsson, J., Zetterberg, H., Blennow, K., Ekman, C.J., Johansson, A., Landén, M., 2012. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder (submitted manuscript).
22. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
23. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
24. Lovinger D.M., White G., Weight F.F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 1989, 243:1721-1724.
25. Luborsky L. Clinician[U+05F3]s judgments of mental health. Arch. Gen. Psychiatry 1962, 7:407-417.
26. Luykx J.J., Bakker S.C., van Boxmeer L., Vinkers C.H., Smeenk H.E., Visser W.F., Verhoeven-Duif N.M., Strengman E., Buizer-Voskamp J.E., de Groene L., van Dongen E.P., Borgdorff P., Bruins P., de Koning T.J., Kahn R.S., Ophoff R.A. d-amino acid aberrations in cerebrospinal fluid and plasma of smokers. Neuropsychopharmacology 2013, 38:2019-2026.
27. Machado-Vieira R., Salvadore G., Ibrahim L.A., Diaz-Granados N., Zarate C.A. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr. Pharm. Des. 2009, 15:1595-1611.
28. Maes M., Verkerk R., Vandoolaeghe E., Lin A., Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr. Scand. 1998, 97:302-308.
29. Mauri M.C., Ferrara A., Boscati L., Bravin S., Zamberlan F., Alecci M., Invernizzi G. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998, 37:124-129.
30. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby C.R., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2006, 30:1155-1158.
31. Ohnuma T., Sakai Y., Maeshima H., Hatano T., Hanzawa R., Abe S., Kida S., Shibata N., Suzuki T., Arai H. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuro-psychopharmacol. Biol. Psychiatry 2008, 32:1905-1912.
32. Olsson S.K., Sellgren C., Engberg G., Landen M., Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012, 14:719-726.
33. Perry T.L., Hansen S., MacLean J. Cerebrospinal fluid and plasma glutamine elevation by anticonvulsant drugs: a potential diagnostic and therapeutic trap. Clin. Chim. Acta 1976, 69:441-445.
34. Pollegioni L., Sacchi S. Metabolism of the neuromodulator d-serine. Cell. Mol. Life Sci. 2010, 67:2387-2404.
35. Rothbaum B.O. Critical parameters for d-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder. Am. J. Psychiatry 2008, 165:293-296.
36. Ryden E., Johansson C., Blennow K., Landen M. Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J. Neural Transm. 2009, 116:1667-1674.
37. Sachs G.S., Thase M.E., Otto M.W., Bauer M., Miklowitz D., Wisniewski S.R., Lavori P., Lebowitz B., Rudorfer M., Frank E., Nierenberg A.A., Fava M., Bowden C., Ketter T., Marangell L., Calabrese J., Kupfer D., Rosenbaum J.F. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 2003, 53:1028-1042.
38. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437.
39. Scholl-Burgi S., Sigl S.B., Haberle J., Haberlandt E., Rostasy K., Ertl C., Eichinger-Ottl U., Heinz-Erian P., Karall D. Amino acids in CSF and plasma in hyperammonaemic coma due to arginase1 deficiency. J. Inherit. Metab. Dis. 2008, 31(Suppl 2):S323-S328.
40. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):S22-S33.
41. Spitzer R.L. Psychiatric diagnosis: are clinicians still necessary?. Compr. Psychiatry 1983, 24:399-411.
42. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005, 10:900-919.
43. Sumiyoshi T., Anil A.E., Jin D., Jayathilake K., Lee M., Meltzer H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int. J. Neuropsychopharmacol. 2004, 7:1-8.
44. Vargas C., Tannhauser M., Barros H.M. Dissimilar effects of lithium and valproic acid on GABA and glutamine concentrations in rat cerebrospinal fluid. Gen. Pharmacol. 1998, 30:601-604.
45. Verity C.M., Applegarth D.A., Farrell K., Kirby L.T. The influence of anticonvulsants on fasting plasma ammonia and amino acid levels. Clin. Biochem. 1983, 16:344-345.